AbbVie Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Robert A. Michael
- Full Time Employees
- 57,000
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 1 North Waukegan Road North Chicago IL United States 60064-6400
- IPO Date
- Jan 2, 2013
- CIK
- 0001551152
- Website
- abbvie.com
- Similar Companies
- Business
- AbbVie Inc. (NYSE: ABBV) is a global research-based biopharmaceutical company that discovers, develops, manufactures and commercializes innovative medicines across immunology, oncology, neuroscience, eye care, aesthetics, virology and gastroenterology. Founded in 2013 as a spin-off from Abbott Laboratories and headquartered in North Chicago, Illinois, the company operates in more than 70 countries with approximately 55,000 employees worldwide. Its core products include Humira (adalimumab) for autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease and ulcerative colitis; Skyrizi (risankizumab) and Rinvoq (upadacitinib), both interleukin inhibitors for immunology indications; Imbruvica (ibrutinib) and Venclexta (venetoclax) for oncology; Vraylar (cariprazine) for schizophrenia and bipolar disorder; Botox for aesthetics; Mavyret (glecaprevir/pibrentasvir) for hepatitis C; and Epkinly (epcoritamab) for blood cancers, among others including Duopa/Duodopa, Ubrelvy and Vyalev in neuroscience and pipeline candidates for Parkinson's disease. AbbVie markets its portfolio to patients, healthcare providers and health systems globally, with major revenue contributions from the United States and international markets. In recent developments, the company completed acquisitions of ImmunoGen for $10.1 billion in 2024 to bolster ovarian cancer treatments with Elahere, Cerevel Therapeutics for $8.7 billion to expand neuroscience, Aliada Therapeutics for $1.4 billion, Nimble Therapeutics and Capstan Therapeutics in 2024-2025 for immunology enhancements, and Gilgamesh Pharmaceuticals in 2025 for a psychiatry drug bretisilocin valued up to $1.2 billion; it also announced partnerships such as $1.64 billion with Neomorph for molecular glue degraders and licensing from Gubra for obesity treatments, alongside over 30 deals since 2024 and manufacturing expansions including a $195 million API facility and $70 million biologics site in the U.S. to support over $10 billion in domestic investments.
Company News
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
Exxon Mobil Just Raised Its Dividend for the 44th Year. Here Are 3 More Wall Street Favorites
Dividend Announcements: October 24-30, 2026 (Part 1 Of 2)
AbbVie expands Oxford R&D facility as part of £120 million-plus investment
AbbVie Hit a New High After Earnings. There's More Upside Left.
Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026
AbbVie Inc. $ABBV Position Lessened by BOCHK Asset Management Ltd
AbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another Test
The Best Dividend Stocks to Buy With $5,000 in November
ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?
4 Elite Dividend Stocks That Pay You Passive Income Every Quarter
2 Safe S&P 500 Healthcare Dividend Stocks Boomers Can Buy and Hold Forever
These Analysts Increase Their Forecasts On AbbVie After Strong Q3 Results
AbbVie, FTAI Aviation, eBay And More: CNBC's ‘Final Trades'
87,345 AbbVie Inc. $ABBV Shares Purchased by Bank Julius Baer & Co. Ltd Zurich
Prediction: AbbVie's Next Blockbuster Is Hiding in a Two-Drug Crohn's Combo
Emerson Among 14 Dividend Growth Companies To Announce Annual Dividend Increases In First Half Of November
AbbVie: 3 Key Takeaways for Long-Term Investors
Is AbbVie a Buy After Its Latest Earnings Report?